NK-cell reconstitution after haploidentical hematopoietic stem-cell transplantations: immaturity of NK cells and inhibitory effect of NKG2A override GvL effect.

Stephanie NguyenVincent Vieillard


Natural killer (NK) cell alloreactivity is reported to mediate strong GvL (graft versus leukemia) effect in patients after haploidentical stem-cell transplantation (SCT) for acute myeloid leukemia (AML). Because subsequent immune reconstitution remains a major concern, we studied NK-cell recovery in 10 patients with AML who received haplomismatched SC transplants, among whom no GvL effect was observed, despite the mismatched immunoglobulin-like receptor (KIR) ligand in the GvH direction for 8 of 10 patients. NK cells generated after SCT exhibited an immature phenotype: the cytotoxic CD3- CD56(dim) subset was small, expression of KIRs and NKp30 was reduced, while CD94/NKG2A expression was increased. This phenotype was associated to in vitro lower levels of cytotoxicity against a K562 cell line and against primary mismatched AML blasts than donor samples. This impaired lysis was correlated with CD94/NKG2A expression in NK cells. Blockading CD94/NKG2A restored lysis against the AML blasts, which all expressed HLA-E, the ligand for CD94/NKG2A. Our present study allows a better understanding of the NK-cell differentiation after SCT. These results revealed that the NK cells generated after haplomismatched SCT are blocked at an immatu...Continue Reading


Jan 26, 1989·The New England Journal of Medicine·C AnasettiE Mickelson
May 1, 1987·Blut·F SigauxJ C Gluckman
Jun 6, 1998·Proceedings of the National Academy of Sciences of the United States of America·W M Yokoyama
Jun 6, 1998·Proceedings of the National Academy of Sciences of the United States of America·N LeeD E Geraghty
May 23, 1998·Annual Review of Immunology·L L Lanier
Dec 23, 1998·European Journal of Immunology·M SalcedoJ P Abastado
Jun 8, 1999·Annual Review of Immunology·C A BironT P Salazar-Mather
Mar 29, 2001·Nature Immunology·L L Lanier
Mar 13, 2001·Annual Review of Immunology·D H RauletC W McMahon
Nov 8, 2001·Trends in Immunology·M A CooperM A Caligiuri
Jan 10, 2002·Proceedings of the National Academy of Sciences of the United States of America·Russell E VanceDavid H Raulet
Feb 6, 2002·The Journal of Experimental Medicine·Laurence Zitvogel
Mar 7, 2002·International Reviews of Immunology·K S Campbell, M Colonna
Mar 28, 2002·Proceedings of the National Academy of Sciences of the United States of America·Simona SivoriAlessandro Moretta
May 8, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Rebecca H LianFumio Takei
Jan 22, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Guido FerlazzoChristian Münz

❮ Previous
Next ❯


Jul 30, 2011·Archivum Immunologiae Et Therapiae Experimentalis·Milena Iwaszko, Katarzyna Bogunia-Kubik
Nov 13, 2008·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Constança FigueiredoRainer Blasczyk
Aug 28, 2009·Cancer Immunology, Immunotherapy : CII·Nicola HardwickFarzin Farzaneh
Feb 2, 2010·Bone Marrow Transplantation·S GiebelJ Holowiecki
Mar 27, 2012·Leukemia·E LionE L J Smits
Dec 17, 2009·Current Opinion in Oncology·Jonathan E BenjaminRobert S Negrin
Sep 10, 2010·Current Opinion in Hematology·Sarah Cooley, Daniel S Weisdorf
Mar 18, 2011·Journal of Innate Immunity·Stéphanie NguyenVincent Vieillard
May 18, 2011·Journal of Innate Immunity·Ariane GrothJoachim Koch
Sep 29, 2010·Medicinski pregled·Svetlana Vojvodić, Stevan Popović
Feb 7, 2013·Journal of Cancer·Jeanne M PalmerSubramaniam Malarkannan
Jul 31, 2012·Clinical & Developmental Immunology·Silke HeidenreichNicolaus Kröger
Mar 13, 2014·Seminars in Immunology·David A KnorrJeffrey S Miller
Aug 11, 2010·Cancer Immunology, Immunotherapy : CII·C J SanchezR T Costello
Feb 12, 2010·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Vincent VieillardUNKNOWN French Asymptomatiques à Long Terme (ALT) ANRS-CO15 Study Group
Nov 9, 2010·Medicinski pregled·Svetlana Vojvodić, Stevan Popović
Apr 14, 2010·Journal of Immunotherapy·Annie MichaudMichel Duval
Nov 21, 2014·Immunopharmacology and Immunotoxicology·Xiao-Hong LiChun-Ji Gao
Dec 10, 2008·International Reviews of Immunology·Syh-Jae LinMing-Ling Kuo
Jan 26, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Monzr M Al MalkiStefan O Ciurea
Oct 1, 2014·Cell Communication and Signaling : CCS·Debanjana ChatterjeeRoland Jacobs

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Adhesion Molecules in the Brain

Cell adhesion molecules found on cell surface help cells bind with other cells or the extracellular matrix to maintain structure and function. Here is the latest research on their role in the brain.

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.